SpyGlass Pharma Stock Price, News & Analysis
Company Description
SpyGlass Pharma (NASDAQ: SGP) is a publicly traded biotechnology company in the Surgical & Medical Instruments & Apparatus sector. The company has a market capitalization of $806.9M, ranking #3,110 among all listed U.S. companies by market cap.
SGP stock has declined 9.8% over the past year. Shares last traded at $23.82.
On a trailing twelve-month basis, SpyGlass Pharma reported net income of -$39.9M and diluted earnings per share of $-17.98.
This page provides a comprehensive overview of SGP stock, including real-time price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.
Stock Performance
SpyGlass Pharma (SGP) stock last traded at $23.82, up 1.30% from the previous close. Over the past 12 months, the stock has lost 9.8%. At a market capitalization of $806.9M, SGP is classified as a small-cap stock with approximately 33.4M shares outstanding.
SGP Rankings
Latest News
SpyGlass Pharma has 6 recent news articles, with the latest published today. Of the recent coverage, 2 articles coincided with positive price movement and 2 with negative movement. Key topics include earnings, clinical trial, IPO, offering. View all SGP news →
SEC Filings
SpyGlass Pharma has filed 5 recent SEC filings, including 2 Form 8-K, 1 Form 10-K, 1 Form SCHEDULE 13G, 1 Form SCHEDULE 13D. The most recent filing was submitted on March 26, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all SGP SEC filings →
Financial Highlights
operating income reached -$41.4M, and net income was -$39.9M. Diluted earnings per share stood at $-17.98. The company generated -$32.7M in operating cash flow. With a current ratio of 12.67, the balance sheet reflects a strong liquidity position.
Upcoming Events
BIM-DRS first-in-human trial
BIM-DRS first-in-human start
Phase 3 enrollment completion
SpyGlass Pharma has 3 upcoming scheduled events. The next event, "BIM-DRS first-in-human trial", is scheduled for July 1, 2026 (in 48 days). Investors can track these dates to stay informed about potential catalysts that may affect the SGP stock price.
Short Interest History
Short interest in SpyGlass Pharma (SGP) currently stands at 1.0 million shares, up 8.1% from the previous reporting period, representing 11.1% of the float. Over the past 12 months, short interest has increased by 474.3%. This moderate level of short interest indicates notable bearish positioning. With 10.8 days to cover, it would take significant time for short sellers to close their positions based on average trading volume.
Days to Cover History
Days to cover for SpyGlass Pharma (SGP) currently stands at 10.8 days, up 90.8% from the previous period. This elevated days-to-cover ratio indicates it would take over two weeks of average trading volume for short sellers to exit their positions, suggesting potential for a short squeeze if positive news emerges. The days to cover has increased 887.2% over the past year, indicating either rising short interest or declining trading volume. The ratio has shown significant volatility over the period, ranging from 1.1 to 10.8 days.
SGP Company Profile & Sector Positioning
SpyGlass Pharma (SGP) operates in the Biotechnology industry within the broader Surgical & Medical Instruments & Apparatus sector and is listed on the NASDAQ. In monthly performance, the stock ranks #2,167 among all tracked companies.